Comparative study of oral and IV dexamethasone premedication in the prevention of docetaxel induced allergic reactions

2021 ◽  
pp. 107815522098436
Author(s):  
Wardah Masood ◽  
Shoaib Shammas ◽  
Zikria Saleem ◽  
Omar Akhlaq Bhutta ◽  
Izzatullah Khan
Keyword(s):  
Information System ◽  
Single Dose ◽  
Hypersensitivity Reaction ◽  
Patient Compliance ◽  
Hospital Information System ◽  
Hypersensitivity Reactions ◽  
Improve Patient Compliance ◽  
Oral Dexamethasone ◽  
The Cost ◽  
Improve Patient

Background The hypersensitivity reactions after docetaxel administration is a main concern in this study. The aim of this study is to check the incidence of hypersensitivity reactions (HSRs) after receiving a single dose of intravenous dexamethasone before docetaxel administration Method In this retrospective study, 1 year data from Jan 1st 2018 to Dec 31st 2018 was retrieved from hospital information system (HIS). We examined 210 patients who visited hospital during the last 12 months during their cancer treatment and took dexamethasone orally 3 days prior to docetaxel administration or 20 mg intravenously before 15 minutes of docetaxel. Results Out of 210 patients, only 50 patients were taking IV dexamethasone injection prior to docetaxel constitutes only 23.5% while patients who were taking oral dexamethasone were found to be 160 which constitutes 75%. There was no hypersensitivity reaction with oral and IV dexamethasone before docetaxel administration. Majority of the patients were without taking oral dexamethasone before docetaxel administration which not only saved time but also improve patient compliance. Conclusion No hypersensitivity reaction had been found either in oral or intravenous dexamethasone prior to docetaxel administration by using patient data from Hospital Information System (HIS). However, intravenous dexamethasone not only improve patient compliance but also reduce the risk of hypersensitivity reactions but the cost of intravenous dexamethasone is higher than the cost of oral dexamethasone. In conclusion, single dose of intravenous IV dexamethasone is preferred treatment option.

Effectiveness of epoetin beta 30,000 UI once weekly (QW) for treatment of anemia in solid tumor patients under chemotherapy

2007 ◽  
Vol 25 (18_suppl) ◽  
pp. 19588-19588
Author(s):  
D. Spaeth ◽  
C. Hennequin ◽  
G. Salles ◽  
T. Facon ◽  
H. Cure ◽  
...  
Keyword(s):  
Patient Compliance ◽  
Solid Tumor ◽  
Performance Status ◽  
Multicenter Trial ◽  
Improve Patient Compliance ◽  
Open Label ◽  
Eligibility Criteria ◽  
Epoetin Beta ◽  
Weekly Treatment ◽  
Improve Patient

19588 Background: Anemia is the most frequent hematological complication of cancer. Epoetin beta (E), an effective treatment of anemia in patients with solid tumors (ST) was administered three-times weekly. However, the QW regimen used in patients with hematological malignancies would be more convenient and may improve patient compliance. The aim of our study was to evaluate efficacy and safety of E 30 000 IU QW in patients with ST. Methods: This study was an open-label, single-arm, multicenter trial carried out in 87 French centers between December 2003 and August 2005. Eligibility criteria were: informed consent, age =18 yrs, WHO performance status 0–2, malignant ST or non-myeloid hematological malignancy, on-going chemotherapy and anemia: hemoglobin (Hb) <12 g/dl. E 30 000 IU QW was administered SC for up to 16 weeks. Follow-up visits were scheduled after each chemotherapy cycle. Primary endpoint was Hb response defined as an Hb increase of =2 g/dl (whatever the baseline Hb level) and/or an achievement of Hb level of =12 g/dl or 13 g/dl (patients with Hb levels <11 g/dl or >11 g/dl at baseline respectively). Delay of Hb response, transfusion requirement, mood and cognitive functions were also assessed. Here we focus specifically on the subgroup of patients with ST. Results: In total, 365 patients with ST were included. The most frequent cancer sites were: lung (102 pts) and breast (86 pts). Median Hb level at baseline was 10.4 g/dl [7.9–12.3]. At endpoint, median Hb level increased to 12.5 g/dl [8.4–15.0]. Hb response rate (RR) was: 61% (IC95: 55–66%), 50% (IC95: 38–55%) in patients treated with platinum based regimen and 72% (IC95 : 62–76%) in patients treated without platinum. RR was 54% in lung (IC95: 44–64%), 76% in breast (IC95: 67- 85%). E treatment was well tolerated. Thromboembolic events occurred in 7% of patients, a rate consistent with information provided in the current label for E. Conclusion: Epoetin beta 30 000 IU once weekly is effective and well tolerated in anemic patients with solid tumor treated with chemotherapy. Once weekly treatment offers a convenient therapy which will improve patient compliance. [Table: see text]

Preoperative Video Instructions Improve Patient Compliance and Satisfaction in Bravo pH Monitoring

2017 ◽  
Vol 152 (5) ◽  
pp. S1261-S1262
Author(s):  
Maureen D. Moore ◽  
Katherine D. Gray ◽  
Suraj Panjwani ◽  
Yining Lu ◽  
Thomas J. Fahey ◽  
...  
Keyword(s):  
Patient Compliance ◽  
Ph Monitoring ◽  
Improve Patient Compliance ◽  
Improve Patient

Shared care programs. Do they improve patient compliance?

2000 ◽  
Vol 151 (1) ◽  
pp. 94
Author(s):  
J. de Velasco ◽  
J.A. Rodriguez ◽  
F. Ridocci
Keyword(s):  
Patient Compliance ◽  
Shared Care ◽  
Improve Patient Compliance ◽  
Improve Patient

scholarly journals Formulation and Evaluation of Ondansetron HCl Nanoparticles for Transdermal Delivery

2020 ◽  
Vol 29 (2) ◽  
pp. 70-79
Author(s):  
Amjed H Noor ◽  
Mowafaq M. Ghareeb
Keyword(s):  
Drug Release ◽  
Zeta Potential ◽  
Patient Compliance ◽  
Transdermal Delivery ◽  
Patient Adherence ◽  
In Vitro Release ◽  
Burst Release ◽  
Improve Patient Compliance ◽  
Improve Patient

Ondansetron HCl (OND) is a potent antiemetic drug used for control of nausea and vomiting associated with cancer chemotherapy. It exhibits only 60 – 70 % of oral bioavailability due to first pass metabolism and has a relative short half-life of 3-5 hours. Poor bioavailability not only leads to the frequent dosing but also shows very poor patient adherence. Hence, in the present study an approach has been made to develop OND nanoparticles using eudragit® RS100 and eudragit® RL100 polymer to control release of OND for transdermal delivery and to improve patient compliance. Six formulas of OND nanoparticles were prepared using nanoprecipitation technique. The particles sizes and zeta potential were measured using zeta-plus analyzer. The particle morphology was also studied using scanning electron microscopy (SEM). The in-vitro release of the drug from the nanoparticles was carried out in phosphate buffer saline pH 7.4. The particle size of the prepared NPs were in nano size which ranged from (95.34 to 275.84 nm) with positive zeta potential. The drug entrapment efficiency was varied with the drug polymer ratio from 41.87% to 78.45%. The SEM showed uniform shape and regularly distributed particle sizes. The in-vitro drug release study exhibited the sustained release of OND with burst release. The cumulative percentage released after 12 hr. were between were 77.89 and 96.01%. Also the transdermal permeation study show that nanoparticles permeate more efficiently than aqueous solution of the drug through the skin by approximately two fold. OND nanoparticles were prepared successfully using nanoprecipitation method. The controlled drug release aimed for transdermal drug delivery could be obtained by using eudragit RS100 and eudragit RL100 polymers which can reduce dosing frequency, decrease side effects and improve patient compliance.

Sign in / Sign up

Export Citation Format

Share Document